This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bioservo Technologies Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Bioservo Technologies şirketinin toplam hissedar öz sermayesi SEK38.5M ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK49.7M ve SEK11.2M dir.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 18.88m
Eşitlik	SEK 38.53m
Toplam yükümlülükler	SEK 11.21m
Toplam varlıklar	SEK 49.74m

Son finansal sağlık güncellemeleri

Is Bioservo Technologies (STO:BIOS) In A Good Position To Deliver On Growth Plans?

Sep 01

Bioservo Technologies (STO:BIOS) Is In A Good Position To Deliver On Growth Plans

Apr 11

We're Not Very Worried About Bioservo Technologies' (STO:BIOS) Cash Burn Rate

Dec 27

Recent updates

Is Bioservo Technologies (STO:BIOS) In A Good Position To Deliver On Growth Plans?

Sep 01

Bioservo Technologies (STO:BIOS) Is In A Good Position To Deliver On Growth Plans

Apr 11

We're Not Very Worried About Bioservo Technologies' (STO:BIOS) Cash Burn Rate

Dec 27

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BIOS 'nin kısa vadeli varlıkları ( SEK44.3M ) kısa vadeli yükümlülüklerini ( SEK10.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: BIOS şirketinin kısa vadeli varlıkları ( SEK44.3M ) uzun vadeli yükümlülüklerini ( SEK1.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BIOS borçsuzdur.

Borcun Azaltılması: BIOS son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: BIOS şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: BIOS tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

This company listing is no longer active

Bioservo Technologies Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Bioservo to Be Delisted from Nasdaq First North

Bioservo Applies for Delisting of its Shares from Nasdaq First North Growth Market

Bioservo Applies for Delisting of its Shares from Nasdaq First North Growth Market

Is Bioservo Technologies (STO:BIOS) In A Good Position To Deliver On Growth Plans?

Bioservo Technologies (STO:BIOS) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Bioservo Technologies' (STO:BIOS) Cash Burn Rate

Recent updates

Bioservo to Be Delisted from Nasdaq First North

Bioservo Applies for Delisting of its Shares from Nasdaq First North Growth Market

Bioservo Applies for Delisting of its Shares from Nasdaq First North Growth Market

New major risk - Share price stability

Third quarter 2023 earnings released

Bioservo Technologies AB (publ) Appoints Annika Rydgård as A New Member of the Management Team

Second quarter 2023 earnings released

Bioservo Technologies AB (Publ) Announces Chief Financial Officer Changes

New major risk - Shareholder dilution

First quarter 2023 earnings released

Full year 2022 earnings released: kr2.66 loss per share (vs kr2.09 loss in FY 2021)

Third quarter 2022 earnings released

Price target decreased to kr8.00

Bioservo Technologies AB (publ) to Report Q3, 2023 Results on Nov 07, 2023

Bioservo Technologies AB (Publ) Announces Carbonhand 2.0 Approves Medical Device According to the EU-MDR

Bioservo Technologies AB (Publ) Announces Carbonhand 2.0 Approves Medical Device According to the EU-MDR

Bioservo Technologies AB (publ) Launches New Assistive Aid for People with Impaired Hand Function

Second quarter 2022 earnings released

Bioservo Technologies AB (Publ) Announces Executive Changes

Bioservo Technologies AB (Publ) Completes Enrollment of Patients for the iHand Clinical Trial

Bioservo Technologies AB (Publ) Preliminary Results from the Ongoing Ihand Study Present At the Congress of the International Federation of Hand Surgery and Hand Therapy in London

First quarter 2022 earnings released

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Bioservo Technologies AB (publ) Receives Certification According to ISO 13485

Third quarter 2021 earnings released

Chairman of the Board recently bought kr149k worth of stock

Is Bioservo Technologies (STO:BIOS) In A Good Position To Deliver On Growth Plans?

Second quarter 2021 earnings released

Bioservo Technologies Releases New Version of the Cutting-Edge Exoskeleton Glove

Bioservo Technologies Releases New Version Ironhand 2.0

First quarter 2021 earnings released

Bioservo Technologies (STO:BIOS) Is In A Good Position To Deliver On Growth Plans

Bioservo Technologies AB (Publ) Announces Claes Mellgren Declines Re-Election At the Annual General Meeting

New 90-day low: kr13.80

Full year 2020 earnings released: kr1.82 loss per share (vs kr2.35 loss in FY 2019)

Bioservo Technologies AB (publ) to Report Fiscal Year 2020 Final Results on Mar 26, 2021

New 90-day high: kr17.65

We're Not Very Worried About Bioservo Technologies' (STO:BIOS) Cash Burn Rate

New 90-day high: kr14.70

New 90-day low: kr10.35

Bioservo Technologies AB (publ) Signs Distribution Agreement with Alpha Quantix in USA

Bioservo Technologies AB Signs Distribution Agreement with G-Hoo in South Korea

New 90-day low: kr11.35

Bioservo Technologies AB (publ) signs distribution agreement with Carl Stahl Hebetechnik GmbH in Germany

Bioservo Technologies AB Signs Distribution Agreement with Tecno Italia S.R.L. for Selling Ironhand® in Italy

Bioservo Technologies AB (publ) Receives Order from Loxam for 18 Ironhand® Systems

First half earnings released

New 90-day high - kr14.55

New 90-day high - kr14.10

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin